Literature DB >> 15708434

Human monoclonal antibodies against amyloid-beta from healthy adults.

Valeria Geylis1, Vitaly Kourilov, Zeev Meiner, Inger Nennesmo, Nenad Bogdanovic, Michael Steinitz.   

Abstract

Two anti-amyloid-beta human antibody-producing cell lines were established from amyloid-beta (Abeta)-selected lymphocytes from peripheral blood of healthy adults. ELISA and Western blot analysis showed that the monoclonal antibodies bound with high affinity to the 43 amino acid-long amyloid-beta peptide. The antigen epitope of these antibodies encountered within amino acids 1-16 of the amyloid-beta peptide. The antibodies did not bind to several immunoglobulin light chain amyloids (AL) and amylin. One of the monoclonals was tested by immunohistochemistry for the binding to frozen sections of brains derived from patients with Alzheimer's disease. It specifically and intensively stained diffuse and core amyloid-beta plaques; whereas, sections from normal brains were not stained. Concomitant staining with a commercial mouse anti-amyloid-beta monoclonal antibody co-localized with that of the human antibody. Simultaneous staining with the human antibody and Congo red implied that the antibody binds primarily to an early immature form of beta-amyloid. Human monoclonal antibodies, which resemble physiologically normal non-pathogenic and possibly protective antibodies in healthy adults, might be attractive candidates for immune therapy of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708434     DOI: 10.1016/j.neurobiolaging.2004.06.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  16 in total

Review 1.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 2.  Central nervous system drug development: an integrative biomarker approach toward individualized medicine.

Authors:  B Gomez-Mancilla; E Marrer; J Kehren; A Kinnunen; G Imbert; R Hillebrand; M Bergström; M E Schmidt
Journal:  NeuroRx       Date:  2005-10

3.  Active Immunization with DNA Vaccine Reduced Cerebral Inflammation and Improved Cognitive Ability in APP/PS1 Transgenic Mice by In Vivo Electroporation.

Authors:  Xiao-Na Xing; Sha Sha; Xiao-Hong Chen; Wan-Shu Guo; Rong Guo; Tong-Zi Jiang; Yun-Peng Cao
Journal:  Neurochem Res       Date:  2015-04-14       Impact factor: 3.996

4.  Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.

Authors:  Chiou-Miin Wang; Sarah Devries; Marybeth Camboni; Matthew Glass; Paul T Martin
Journal:  Neurobiol Dis       Date:  2010-05-20       Impact factor: 5.996

5.  Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies.

Authors:  Malin Lindhagen-Persson; Kristoffer Brännström; Monika Vestling; Michael Steinitz; Anders Olofsson
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

6.  MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice.

Authors:  Bin Liu; Jeffrey L Frost; Jing Sun; Hongjun Fu; Stephen Grimes; Peter Blackburn; Cynthia A Lemere
Journal:  J Neurosci       Date:  2013-04-17       Impact factor: 6.167

Review 7.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

8.  Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.

Authors:  William A Banks; Susan A Farr; John E Morley; Kathy M Wolf; Valeria Geylis; Michael Steinitz
Journal:  Exp Neurol       Date:  2007-05-22       Impact factor: 5.330

9.  Yeast expressed foldable quadrivalent Aβ15 elicited strong immune response against Aβ without Aβ-specific T cell response in wild C57BL/6 mice.

Authors:  Lin Tan; Hao Wang; Xin Tan; Juntao Zou; Zhibin Yao
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

10.  Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease.

Authors:  Andrea Marcello; Oliver Wirths; Thomas Schneider-Axmann; Malin Degerman-Gunnarsson; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-05-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.